Recent advances and current challenges in CAR-T cell therapy

Joy, R.; Phair, K.; O’Hara, R.; Brady, D.

doi:10.1007/s10529-023-03461-0

Cited by 6 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, CAR-T cells are engineered to precisely recognize and attack specific antigens on the surface of cancer cells, minimizing damage to normal cells. This provides a more accurate and targeted therapeutic option [ 69 , 70 ]. Multiple CAR-T therapies have been found to inhibit melanoma progression in preclinical studies [ 71 , 72 ].…”

Section: Mafs As Targets In Cancer Immunotherapymentioning

confidence: 99%

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Zhou,

Jin,

Zhao

et al. 2024

Human Molecular Genetics

View full text Add to dashboard Cite

Melanoma, renowned for its aggressive behavior and resistance to conventional treatments, stands as a formidable challenge in the oncology landscape. The dynamic and complex interplay between cancer cells and the tumor microenvironment has gained significant attention, revealing Melanoma-Associated Fibroblasts (MAFs) as central players in disease progression. The heterogeneity of MAFs endows them with a dual role in melanoma. This exhaustive review seeks to not only shed light on the multifaceted roles of MAFs in orchestrating tumor-promoting inflammation but also to explore their involvement in antitumor immunity. By unraveling novel mechanisms underlying MAF functions, this review aims to provide a comprehensive understanding of their impact on melanoma development. Additionally, it delves into the potential of leveraging MAFs for innovative immunotherapeutic strategies, offering new avenues for enhancing treatment outcomes in the challenging realm of melanoma therapeutics.

show abstract

Section: Mafs As Targets In Cancer Immunotherapymentioning

confidence: 99%

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Zhou,

Jin,

Zhao

et al. 2024

Human Molecular Genetics

View full text Add to dashboard Cite

show abstract

“…Chimeric antigen receptor-modified T-cell (CAR-T) is a clinical and technological revolution ( 1 , 2 ). The more advanced developments that led to the commercialization of the first products, have identified as a target the molecule CD19, expressed in all leukemia acute lymphoblastic leukemia (ALL) ( 3 ) and in Non-Hodgkin Lymphoma (NHL) ( 4 ), such as diffuse (D) large B-cell lymphoma (LBCL) ( 5 ), follicular lymphoma (FL) ( 6 ), mantle-cel lymphoma (MCL) ( 7 ) and the molecule B-cell maturation antigen (BCMA), expresses in multiple myeloma (MM) ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Martino,

Porto,

Policastro

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma

Balanean,

Baird,

Dulka

et al. 2024

eJHaem

View full text Add to dashboard Cite

IntroductionInitially approved for the fifth‐line or later therapeutic setting, the chimeric antigen receptor (CAR) T‐cell regimen ciltacabtagene autoleucel (cilta‐cel) was recently approved for second‐line (2L) treatment in relapsed/refractory multiple myeloma (RRMM). Oncology practitioners use clinical trials to inform treatment, but real‐world impressions and impact on practice are lacking. We aimed to determine whether presenting CARTITUDE‐4 clinical trial data would impact real‐world preferences/perceptions around CAR T‐cell therapy.MethodsRecruiting from the Cardinal Health Oncology Provider Extended Network (OPEN), we surveyed hematologists/oncologists to investigate fourth‐line (4L) preferences in a hypothetical patient with triple‐class–refractory MM. We posed the same questions and answers before and after the trial presentation and compared pre‐/post‐preferences toward cilta‐cel and sequencing relative to bispecific antibodies (BsAbs). Using the same methodology as described above, we also performed a secondary analysis comparing pre‐/post‐perceptions on the use of CAR T‐cell therapy in earlier lines for patients with triple‐class–refractory MM.ResultsAmong 50 respondents, decision‐making factors before the trial presentation included CAR T‐cell center availability (58%), comorbidities (52%), and center locations (34%). Additionally, 48% of 46 respondents chose 4L cilta‐cel. Among 47, 40% wanted more real‐world/long‐term CAR T‐cell therapy outcomes in any line, 38% wanted more 2L data, and 34% favored 2L/third‐line (3L) use. After the presentation, the preference for cilta‐cel doubled from 48% to 88% (p < 0.001) among 50 respondents and rose from 34% to 55% (p = 0.001) for earlier‐line CAR T‐cell therapy among 49. Moreover, 55% of 49 respondents preferred CAR T‐cell therapy prior to BsAbs.DiscussionWe have shown that making oncology practitioners aware of trials precipitated decision‐making factors and led to notable, significant shifts in future intended practice patterns. Being aware of trial data enables practitioners to make more informed decisions, tailor therapies to individual patients, and ultimately improve outcomes.

show abstract

Recent advances and current challenges in CAR-T cell therapy

Cited by 6 publications

References 42 publications

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies

Effectiveness of CAR-T treatment toward the potential risk of second malignancies

Real‐world practitioner perceptions of CARTITUDE‐4 results for patients with previously treated multiple myeloma

Contact Info

Product

Resources

About